Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | KCNA1 | Q09470 | 2/20 | 0.48 |
| ▸ | KCNAB1 | Q14722 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8149885 | 0.96 | NPC1 (0.58) | NPC1RAB9AESR2NR1H2GPR119 | |
| SCHEMBL4789781 | 0.93 | ESR2 (0.66) | NPC1RAB9AESR2NR1H2GPR119 | |
| SCHEMBL5600152 | 0.93 | NR1H2 (0.65) | NPC1RAB9AESR2NR1H2GPR119 | |
| SCHEMBL5778881 | 0.86 | KCNA1 (0.57) | NPC1RAB9AESR2NR1H2KCNA1 | |
| SCHEMBL18423515 | 0.85 | PTPN1 (0.55) | NPC1RAB9AESR2NR1H2GPR119 | |
| SCHEMBL6365439 | 0.84 | KCNA1 (0.60) | NPC1RAB9AESR2NR1H2KCNA1 | |
| SCHEMBL6393284 | 0.84 | PTPN1 (0.64) | NPC1RAB9AESR2NR1H2PTPN1 | |
| SCHEMBL5440052 | 0.84 | KCNA1 (0.56) | NPC1RAB9AESR2NR1H2KCNA1 | |
| SCHEMBL2310073 | 0.84 | NPC1 (0.66) | NPC1RAB9AESR2NR1H2GPR119 | |
| SCHEMBL5434427 | 0.83 | KCNA1 (0.55) | NPC1RAB9AESR2KCNA1KCNAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| EP-0284384-B1 | ANTI-ARRHYTHMIC AGENTS | Pfizer Limited (GB) | 1990-11-28 | — | — | EP | disclosed |
| US-4891372-A | Antiarrhythmic agents, compositions and method of use thereas | PFIZER INC. (US) | 1990-01-02 | — | — | US | disclosed |
| EP-0284384-A1 | Anti-arrhythmic agents | Pfizer Limited (GB) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | NPC1 952/4885RAB9A 1460/4885ESR2 960/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | NPC1 921/4885RAB9A 1377/4885ESR2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.